Phase 3 Irritable Bowel Syndrome Trial, Recruiting (NCT03613545)

Phase 3 Irritable Bowel Syndrome Trial, Recruiting NCT03613545 Sponsor: Guangzhou First People's Hospital Condition: Irritable Bowel Syndrome

Printed from Voxsanity (voxsanity.com.au) — NCT03613545 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Irritable Bowel Syndrome

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be able to read and sign a consent form agreeing to take part in the study.
You must be male or female, aged between 18 and 75 years old.
You must have been diagnosed with Irritable Bowel Syndrome (IBS) based on a specific set of recognised medical guidelines called the Rome IV criteria (confirm with trial site).

Who may not be able to join:

You may not be able to join if you are pregnant or if you are unable to commit to at least 6 months of follow-up appointments.
You may not be able to join if you are unable to read or sign a consent form agreeing to take part.
You may not be able to join if you have another serious illness, such as liver or kidney failure, cancer, other intestinal diseases, inflammatory bowel disease, or a type of gut infection called C. difficile.
You may not be able to join if you are unable to have a camera procedure to look inside your digestive system (called an endoscopy).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hongli Huang, MM, Guangzhou First People's Hospital

Phone: 86-13631316718

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03613545

Sponsor: Guangzhou First People's Hospital

Phase: Phase 3

Status: Recruiting

Condition: Irritable Bowel Syndrome

Trial contact: 86-13631316718

More information: https://clinicaltrials.gov/study/NCT03613545

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be able to read and sign a consent form agreeing to take part in the study.
You must be male or female, aged between 18 and 75 years old.
You must have been diagnosed with Irritable Bowel Syndrome (IBS) based on a specific set of recognised medical guidelines called the Rome IV criteria (confirm with trial site).

Who may not be able to join:

You may not be able to join if you are pregnant or if you are unable to commit to at least 6 months of follow-up appointments.
You may not be able to join if you are unable to read or sign a consent form agreeing to take part.
You may not be able to join if you have another serious illness, such as liver or kidney failure, cancer, other intestinal diseases, inflammatory bowel disease, or a type of gut infection called C. difficile.
You may not be able to join if you are unable to have a camera procedure to look inside your digestive system (called an endoscopy).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Guangzhou First People's Hospital

Registry

ClinicalTrials.gov

Start date

10 August 2018

Est. completion

31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in Irritable Bowel Syndrome assessed by Symptom Severity Score (IBS-SSS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov